UroGen Pharma Ltd.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Non-accelerated filerSmaller reporting company
State of Incorporation
Israel
Business Address
9 HA'TA'ASIYA ST, RA'ANANA, L3, 4365007
Mailing Address
9 HA'TA'ASIYA ST, RA'ANANA, L3, 4365007
Phone
972 9 770 7601
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2025
-$126.87M
Net Income
$285.71M
Total Assets
$305.93M
Total Liabilities
$171.99M
Cash & Equivalents
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 10-K Annual financial report | March 2, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 8-K Current report of material events | March 2, 2026 | View on SEC |
| 4 Insider stock transaction report | February 27, 2026 | View on SEC |
| 4 Insider stock transaction report | February 19, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 13, 2026 | View on SEC |
| 4 Insider stock transaction report | February 11, 2026 | View on SEC |
| 4 Insider stock transaction report | February 4, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
| 4 Insider stock transaction report | February 3, 2026 | View on SEC |
Annual Reports
10-K
March 2, 2026
- Early 2025 FDA approval of Zusduri (UGN-102) for LG-IR-NMIBC, significantly expanding the product portfolio.
- 25% increase in total revenue to $75 million in 2024, primarily driven by Jelmyto sales.
Insider Trading
STRONG SELL
2 insiders
7 recent transactions
View Full Insider Trading Profile
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.